How were the tax obligations handled for the AVNS CEO’s vested restricted share units?

Tax obligations were met by surrendering 21,194 shares of common stock to Avanos Medical. These shares covered withholding taxes arising when 72,614 time-based restricted share units vested, avoiding a separate cash payment and classifying the transaction as tax withholding, not a market sale.

AVNS CEO surrenders shares for tax withholding

AVANOS MEDICAL, INC.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AVANOS MEDICAL, INC. Chief Executive Officer David Pacitti reported a routine tax-related share disposition. He surrendered 21,194 shares of Common Stock at $14.53 per share to the company to cover tax withholding due when 72,614 time-based restricted share units vested. After this tax-withholding transaction, he directly holds 322,194 shares of Common Stock.

Insider Trade Summary

Exercise Price or Tax Liability: 21,194 shares

Exercise Price or Tax Liability 1 txn

Insider Pacitti David

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	21,194	$14.53	$308K

Holdings After Transaction: Common Stock — 322,194 shares (Direct)

Footnotes (1)

F1. Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 72,614 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person on April 14, 2025 and (ii) vested on April 14, 2026. Each TRSU is the economic equivalent of one share of Common Stock.

Key Figures

Shares surrendered for taxes: 21,194 shares Price per share for tax calculation: $14.53 per share Shares held after transaction: 322,194 shares +3 more

6 metrics

Shares surrendered for taxes 21,194 shares Tax withholding disposition of common stock

Price per share for tax calculation $14.53 per share Value used on surrendered shares

Shares held after transaction 322,194 shares Direct common stock ownership post-transaction

Time-based RSUs vested 72,614 units TRSUs vesting that triggered tax withholding

RSU grant date April 14, 2025 Award date for 72,614 TRSUs

RSU vesting date April 14, 2026 Vesting date for 72,614 TRSUs

Key Terms

time-based restricted share units, TRSUs, tax withholding obligations, Common Stock

4 terms

TRSUs financial

"72,614 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person"

tax withholding obligations financial

"Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting"

Common Stock financial

"Each TRSU is the economic equivalent of one share of Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AVNS CEO David Pacitti report on this Form 4?

CEO David Pacitti reported a tax-related disposition of 21,194 shares of Avanos Medical common stock. The shares were surrendered to the company to satisfy tax withholding obligations tied to the vesting of time-based restricted share units, not sold on the open market.

Was the AVNS CEO’s Form 4 transaction an open-market sale of shares?

No, the transaction was not an open-market sale. The 21,194 shares were surrendered back to Avanos Medical to cover tax withholding obligations when restricted share units vested, making this a mechanistic tax-withholding event rather than a discretionary sale in the market.

How many Avanos Medical shares does CEO David Pacitti hold after this Form 4 transaction?

After the tax-withholding disposition, David Pacitti holds 322,194 shares of Avanos Medical common stock directly. This figure reflects his position following the surrender of 21,194 shares to satisfy tax obligations related to the vesting of time-based restricted share units.

What equity award vested for the AVNS CEO in connection with this Form 4?

A grant of 72,614 time-based restricted share units vested for the CEO. Each unit is economically equivalent to one share of Avanos Medical common stock, and the vesting triggered tax withholding that was satisfied by surrendering 21,194 shares back to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/16/2026 - 04:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pacitti David

(Last)

(First)

(Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA

GEORGIA

30004

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/14/2026		F⁽¹⁾		21,194	D	$14.53	322,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects shares surrendered to the Issuer to satisfy tax withholding obligations upon the vesting of 72,614 time-based restricted share units (TRSUs) which: (i) were awarded to the Reporting Person on April 14, 2025 and (ii) vested on April 14, 2026. Each TRSU is the economic equivalent of one share of Common Stock.

Remarks:

	/s/ John Hurley, as attorney-in-fact for David Pacitti	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR